Advancing treatment choices: CDK4/6 inhibitor switching in HR+/HER2- metastatic breast cancer.

ABSTRACT:

Purpose

CDK4/6 inhibitors (CDK4/6i) use has revolutionized the treatment of hormone receptor-positive/human epidermal growth factor receptor 2 negative (HR+/HER2-) metastatic breast cancer. The choice of a specific CDK4/6i may be influenced by adverse events (AEs). Recently, the Italian Medicines Agency (AIFA) approved the possibility of switching between CDK4/6i for unacceptable toxicity. This study explores oncologists' experiences and future perspectives on CDK4/6 inhibitor switching following this new approval.

Methods

With the support of the Italian Association of Medical Oncology (AIOM), we conducted a survey among 92 oncologists to assess the impact of AIFA's approval on patient management.

Results

The survey showed that 48 % of participants were not surprised

SUBMITTER: Zagami P 

PROVIDER: S-EPMC11786079 | biostudies-literature | 2025 Feb

REPOSITORIES: biostudies-literature